Metabolic remission with octreotide in patients with insulinoma.

Abstract

OBJECTIVES:

The efficacy of octreotide was studied in a group of patients with biochemical evidence of insulinoma.

DESIGN:

A phase-II study.

SETTING:

A university department of internal medicine.

SUBJECTS:

Seven patients with biochemical evidence of insulinoma and without metastatic lesions.

INTERVENTION:

Daily treatment with octreotide, a somatostatin analogue, mainly within the dosage of 100-300 micrograms day-1. The treatment was continued in patients with biochemical evidence of response or until surgery was undertaken.

MAIN OUTCOME:

Five patients avoided hypoglycaemic symptoms and had normalization of blood glucose values for a median of 15+ months (range 0.2-54 months). Two did not improve metabolically. The treatment was well tolerated and had no deleterious effects on blood glucose regulation.

CONCLUSION:

Octreotide seems to be a promising treatment for many of the patients with insulinoma who are not suitable for surgery.

• Authors: F E von Eyben, E Grodum, H J Gjessing, C Hagen, H Nielsen
• Journal: Journal of internal medicine (J Intern Med) Vol. 235 Issue 3 Pg. 245-8 (Mar 1994) ISSN: 0954-6820 [Print] England
• PMID: 8120520 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)

Chemical References

• Octreotide

Topics

• Adult
• Aged
• Female
• Humans
• Insulinoma (blood, drug therapy)
• Male
• Middle Aged
• Octreotide (therapeutic use)
• Pancreatic Neoplasms (blood, drug therapy)
• Prospective Studies
• Time Factors
• Treatment Outcome